Cincinnati Pediatric Clinical Pharmacology Postdoctoral Training Program

辛辛那提儿科临床药理学博士后培训项目

• 批准号: 9918428
• 负责人: Alexander A Vinks
• 金额: $ 20.35万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-16 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9918428
• 关键词: Childhood; Clinical Pharmacology; Training Programs; post-doctoral training

 DESCRIPTION (provided by applicant): The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCOM). This T32 Training Program also involves strong collaborations with the James L. Winkle College of Pharmacy and the Departments of Pharmacology & Cell Biophysics and Biomedical Informatics at the UCCOM. The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in clinical pharmacology research representing 12 divisions within the Department of Pediatrics and 4 Departments at the University of Cincinnati. The program has strong institutional support and takes advantage of a variety of advanced technologies and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as physiologically based PK/PD modeling, systems pharmacology and quantitative modeling and simulation and in silico clinical trial design; (3) is embedded in the institutional and Academic Health Center's pharmacogenetic/genomics research and training endeavors of the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; (5) can rely on over ten years of experience as one of 13 sites of the Pediatric Pharmacology Research Unit (PPRU) network, and on one funding cycle as a successful training program. The program provides a unique training experience and has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics. The training program allows postdoctoral fellows to acquire a refined vision for applying state of the art principles of pediatrics clinical pharmacology to clinical research and evidence- based practice with the goal to improve therapeutics and health outcomes in children.

 描述（由申请人提供）：对儿科临床药理学研究和培训的需求从未如此强烈，辛辛那提儿童医院医疗中心 (CCHMC) 的儿科临床药理学 T32 培训计划专门为满足这一关键需求而设计。临床药理学部是儿科和辛辛那提大学医学院 (UCCOM) 的联合单位。该 T32 培训计划还涉及与以下机构的密切合作。 James L. Winkle 药学院以及 UCCOM 的药理学、细胞生物物理学和生物医学信息学系本次更新申请中概述的计划依靠强大的领导力和积极参与临床药理学研究的多元化教师导师群体。该项目由辛辛那提大学儿科的 12 个科室和 4 个系组成，并在独特的协作环境中利用了各种先进技术和资源。培训计划具有创新性，并且与计划公告中概述的目标非常一致，因为：（1）通过与所有主要儿科亚专业的持续研究合作，重点关注多个不同儿科人群的早期和后期研究；（2）创新定量方法的应用和开发，例如基于生理学的 PK/PD 建模、系统药理学和定量建模与模拟以及计算机临床试验设计（3）融入机构和学术健康中心的药物遗传学/基因组学研究和培训工作中；中心的儿科基因组学；(4) 与生物信息学、健康服务和结果研究紧密结合；(5) 作为儿科药理学研究单位 (PPRU) 网络的 13 个研究中心之一，拥有超过 10 年的经验，并依靠一项资助作为一个成功的培训计划，该计划提供了独特的培训经验，并成功地开辟了新的途径，以扩大对儿科治疗有职业兴趣的有才华的年轻临床研究人员。将最先进的儿科临床药理学原理应用于临床研究和循证实践，以改善儿童的治疗和健康结果为目标。